Abstract
Immune checkpoint inhibitors have become one of the pillars of cancer treatment, but may be associated with a wide range of potential adverse effects. In this review, we discuss the presentation and management of immune-related adverse events according to their severity and organ system involvement. Tables with management guidelines are included.